Durable complete remission of a brainstem glioma treated with a combination of bevacizumab and cetuximab.
Treatment of a relapsed glioma is a clinical challenge nowadays. New active treatments are required to treat these difficult diseases. Here we present a durable complete remission of a relapsed glioblastoma that has achieved a complete radiologic response with the combination of cetuximab and bevacizumab, in a third-line setting, that has offered a progression-free survival of 20 months. We consider here both potential mechanisms for the explanation of this result. First, the potential target of the cancer stem cells (CSCs) with these two antibodies, and second, the potential recruitment of the immune system to directly pursue the CSCs.
Department of Medical Oncology, Hospital de Dénia, Marina Salud, Dénia, Spain.
Joan Manel Gasent
JM
Blesa
Sara Blasco
SB
Mollá
María Fonfría
MF
Esparcia
José Miguel Sempere
JM
Ortells
Miguel Peris
MP
Godoy
Adrian Munilla
AM
Das
Balbino Mancheño
BM
Magan
Mariano Provencio
MP
Pulla
Jose Luis
JL
Sanchez
Juan Bautista Laforga
JB
Canales
Vicente Alberola
VA
Candel
Bevacizumab; Cetuximab; Durable remission; Glioma